Enrollment in aTyr Pharma’s pivotal Phase 3 EFZO-FIT clinical trial, testing the effectiveness and safety of efzofitimod in people with pulmonary sarcoidosis, is now complete. The study exceeded its target number of participants, recruiting 268 patients in 85 centers across the U.S., Europe, Japan, and Brazil. Top-line data are expected…
Search results for:
Recent research on sarcoidosis highlights several developments: * **Clinical Trials:** Enrollment is complete for the Phase 3 trial of efzofitimod, while a Phase 2 trial is recruiting for Novartis's CMK389. * **Triggers & Mechanisms:** Microblading may trigger systemic sarcoidosis, and an immune cell imbalance may promote the disease. * **Diagnosis:** Analyzing lung fluid ratios could improve diagnosis.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
Microblading, a cosmetic technique that employs fine needles to deposit pigment to mimic the appearance of hairs, may be among triggers for sarcoidosis, according to a study. “When esthetic procedures become increasingly popular, patients with chronic lesions at the injection site of the foreign material, especially macular, papular, or…
Researchers have discovered that patients with pulmonary sarcoidosis have an imbalance in two subsets of immune cells, namely B-cells and follicular T-helper cells — findings that support the potential role of autoimmune mechanisms in sarcoidosis development. The study, “Imbalance in B cell and T Follicular Helper…
Analyzing the bronchoalveolar lavage fluid (called BALF, it is a small sample of the fluid present in the lungs) for the ratio of immune CD4 and CD8 cells may improve the diagnosis of sarcoidosis, according to the results of a recent study. BALF is collected through a medical procedure using a bronchoscope that is…
A Phase 2 clinical trial is recruiting adults with chronic pulmonary sarcoidosis to investigate the safety and therapeutic potential of CMK389 in improving lung function. CMK389 is an investigational therapy, developed by Novartis, for the treatment of pulmonary sarcoidosis and atopic dermatitis. It was designed to inhibit interleukin 18,…
Genome-wide analysis of lung samples from pulmonary sarcoidosis patients and a healthy control group identified a set of genes whose expression is altered only in disease samples. These results may lead to new biomarkers for pulmonary sarcoidosis. The study, “Bioinformatics analysis of gene expression profile data to screen key…
A study shows therapeutic doses of Atyr Pharma’s experimental therapy efzofitimod were associated with a lower rate of relapse in people with pulmonary sarcoidosis who were tapering oral corticosteroids, a mainstay treatment linked with toxic side effects when given for long periods and at high doses. While the…
A literature review of research performed in specific populations from countries worldwide estimated a heritability of 60 to 70 percent for familial sarcoidosis, a study has found. The study titled “Clinical epidemiology of familial sarcoidosis: A systematic literature review” was published in the journal Respiratory Medicine. While the…
Lower expression of a receptor at the surface of immune cells, called monocytes, in the blood of sarcoidosis patients is linked to disease development. The study “Reduced expression of monocyte CD200R is associated with enhanced proinflammatory cytokine production in sarcoidosis” was published in the journal Scientific…
News
LAS System May Fail to Identify Sarcoidosis Patients at Urgent Need of Lung Transplant, Study Finds
The current scoring system used to assess the urgency of lung transplants, called LAS (lung allocation score), fails to predict the risk of death in people with sarcoidosis, a single center study suggests. The study “Mortality for sarcoidosis patients on the transplant wait list in the…